Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

The old becomes new: advances in imaging techniques to assess nephron mass in children.

DeFreitas MJ, Katsoufis CP, Infante JC, Granda ML, Abitbol CL, Fornoni A.

Pediatr Nephrol. 2020 Jan 17. doi: 10.1007/s00467-020-04477-8. [Epub ahead of print]

PMID:
31953750
2.

Crosstalk Between Lipids and Mitochondria in Diabetic Kidney Disease.

Ducasa GM, Mitrofanova A, Fornoni A.

Curr Diab Rep. 2019 Nov 21;19(12):144. doi: 10.1007/s11892-019-1263-x. Review.

PMID:
31754839
3.

Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis.

Otalora L, Chavez E, Watford D, Tueros L, Correa M, Nair V, Ruiz P, Wahl P, Eddy S, Martini S, Kretzler M, Burke GW 3rd, Fornoni A, Merscher S.

PLoS One. 2019 Oct 3;14(10):e0222948. doi: 10.1371/journal.pone.0222948. eCollection 2019.

4.

Lipid mediators of insulin signaling in diabetic kidney disease.

Mitrofanova A, Sosa MA, Fornoni A.

Am J Physiol Renal Physiol. 2019 Nov 1;317(5):F1241-F1252. doi: 10.1152/ajprenal.00379.2019. Epub 2019 Sep 23.

PMID:
31545927
5.

Regulation of the amount of ceramide-1-phosphate synthesized in differentiated human podocytes.

Mallela SK, Mitrofanova A, Merscher S, Fornoni A.

Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Dec;1864(12):158517. doi: 10.1016/j.bbalip.2019.158517. Epub 2019 Sep 2.

6.

ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes.

Ducasa GM, Mitrofanova A, Mallela SK, Liu X, Molina J, Sloan A, Pedigo CE, Ge M, Santos JV, Hernandez Y, Kim JJ, Maugeais C, Mendez AJ, Nair V, Kretzler M, Burke GW, Nelson RG, Ishimoto Y, Inagi R, Banerjee S, Liu S, Szeto HH, Merscher S, Fontanesi F, Fornoni A.

J Clin Invest. 2019 Jul 22;129(8):3387-3400. doi: 10.1172/JCI125316. eCollection 2019 Jul 22.

7.

Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease.

Niezen S, Diaz Del Castillo H, Mendez Castaner LA, Fornoni A.

Endocrinol Diabetes Metab. 2019 May 17;2(3):e00072. doi: 10.1002/edm2.72. eCollection 2019 Jul. Review.

8.

SMPDL3b modulates insulin receptor signaling in diabetic kidney disease.

Mitrofanova A, Mallela SK, Ducasa GM, Yoo TH, Rosenfeld-Gur E, Zelnik ID, Molina J, Varona Santos J, Ge M, Sloan A, Kim JJ, Pedigo C, Bryn J, Volosenco I, Faul C, Zeidan YH, Garcia Hernandez C, Mendez AJ, Leibiger I, Burke GW, Futerman AH, Barisoni L, Ishimoto Y, Inagi R, Merscher S, Fornoni A.

Nat Commun. 2019 Jun 19;10(1):2692. doi: 10.1038/s41467-019-10584-4.

9.

Histological Evidence of Diabetic Kidney Disease Precede Clinical Diagnosis.

Comai G, Malvi D, Angeletti A, Vasuri F, Valente S, Ambrosi F, Capelli I, Ravaioli M, Pasquinelli G, D'Errico A, Fornoni A, La Manna G.

Am J Nephrol. 2019;50(1):29-36. doi: 10.1159/000500353. Epub 2019 Jun 5.

PMID:
31167184
10.

Detection and Quantification of Lipid Droplets in Differentiated Human Podocytes.

Mallela SK, Patel DM, Ducasa GM, Merscher S, Fornoni A, Al-Ali H.

Methods Mol Biol. 2019;1996:199-206. doi: 10.1007/978-1-4939-9488-5_17.

PMID:
31127558
11.

APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice.

Ryu JH, Ge M, Merscher S, Rosenberg AZ, Desante M, Roshanravan H, Okamoto K, Shin MK, Hoek M, Fornoni A, Kopp JB.

PLoS One. 2019 Apr 18;14(4):e0211559. doi: 10.1371/journal.pone.0211559. eCollection 2019.

12.

Health-related quality of life in glomerular disease.

Canetta PA, Troost JP, Mahoney S, Kogon AJ, Carlozzi N, Bartosh SM, Cai Y, Davis TK, Fernandez H, Fornoni A, Gbadegesin RA, Herreshoff E, Mahan JD, Nachman PH, Selewski DT, Sethna CB, Srivastava T, Tuttle KR, Wang CS, Falk RJ, Gharavi AG, Gillespie BW, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Guay-Woodford LM, Reeve B, Gipson DS; CureGN Consortium.

Kidney Int. 2019 May;95(5):1209-1224. doi: 10.1016/j.kint.2018.12.018. Epub 2019 Feb 27.

PMID:
30898342
13.

The elusive podocyte crossmatch for recurrent focal segmental glomerulosclerosis.

Burke GW 3rd, Fornoni A.

Kidney Int. 2019 Mar;95(3):498-500. doi: 10.1016/j.kint.2018.11.032.

PMID:
30784659
14.

DNA-Encoded Library-Derived DDR1 Inhibitor Prevents Fibrosis and Renal Function Loss in a Genetic Mouse Model of Alport Syndrome.

Richter H, Satz AL, Bedoucha M, Buettelmann B, Petersen AC, Harmeier A, Hermosilla R, Hochstrasser R, Burger D, Gsell B, Gasser R, Huber S, Hug MN, Kocer B, Kuhn B, Ritter M, Rudolph MG, Weibel F, Molina-David J, Kim JJ, Santos JV, Stihle M, Georges GJ, Bonfil RD, Fridman R, Uhles S, Moll S, Faul C, Fornoni A, Prunotto M.

ACS Chem Biol. 2019 Jan 18;14(1):37-49. doi: 10.1021/acschembio.8b00866. Epub 2018 Dec 16.

15.

Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.

Mitrofanova A, Molina J, Varona Santos J, Guzman J, Morales XA, Ducasa GM, Bryn J, Sloan A, Volosenco I, Kim JJ, Ge M, Mallela SK, Kretzler M, Eddy S, Martini S, Wahl P, Pastori S, Mendez AJ, Burke GW, Merscher S, Fornoni A.

Kidney Int. 2018 Dec;94(6):1151-1159. doi: 10.1016/j.kint.2018.06.031. Epub 2018 Oct 6.

16.

Probing insulin sensitivity in diabetic kidney disease: is there a stronger role for functional imaging?

Granda ML, Amarapurkar P, Fornoni A.

Clin Sci (Lond). 2018 Jun 5;132(11):1085-1095. doi: 10.1042/CS20171490. Print 2018 Jun 14. Review.

PMID:
29871909
17.

Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE.

Nat Rev Nephrol. 2017 Dec 13;14(1):70. doi: 10.1038/nrneph.2017.175.

PMID:
29234164
18.

Translational Aspects of Sphingolipid Metabolism in Renal Disorders.

Abou Daher A, El Jalkh T, Eid AA, Fornoni A, Marples B, Zeidan YH.

Int J Mol Sci. 2017 Nov 25;18(12). pii: E2528. doi: 10.3390/ijms18122528. Review.

19.

Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE.

Nat Rev Nephrol. 2018 Jan;14(1):57-70. doi: 10.1038/nrneph.2017.155. Epub 2017 Nov 27. Review. Erratum in: Nat Rev Nephrol. 2017 Dec 13;14 (1):70.

20.

Regulator of G-protein signaling Gβ5-R7 is a crucial activator of muscarinic M3 receptor-stimulated insulin secretion.

Wang Q, Pronin AN, Levay K, Almaca J, Fornoni A, Caicedo A, Slepak VZ.

FASEB J. 2017 Nov;31(11):4734-4744. doi: 10.1096/fj.201700197RR. Epub 2017 Jul 7.

21.

Direct Measurement of Free and Esterified Cholesterol Mass in Differentiated Human Podocytes: A TLC and Enzymatic Assay-Based Method.

Pedigo CE, Merscher SM, Fornoni A.

Methods Mol Biol. 2017;1609:51-56. doi: 10.1007/978-1-4939-6996-8_6.

22.

Engineering human renal epithelial cells for transplantation in regenerative medicine.

Manzoli V, Colter DC, Dhanaraj S, Fornoni A, Ricordi C, Pileggi A, Tomei AA.

Med Eng Phys. 2017 Oct;48:3-13. doi: 10.1016/j.medengphy.2017.03.009. Epub 2017 Apr 14.

23.

Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes.

Ahmad A, Mitrofanova A, Bielawski J, Yang Y, Marples B, Fornoni A, Zeidan YH.

FASEB J. 2017 Feb;31(2):771-780. doi: 10.1096/fj.201600618R. Epub 2016 Nov 11.

24.

Ten Years of Preserved Kidney Function After Islet Transplant Graft Failure.

Peixoto E, Vendrame F, Arnau A, Padilla N, Baidal D, Alvarez A, Delmonte V, Fornoni A, Ricordi C, Alejandro R.

Diabetes Care. 2016 Dec;39(12):e209-e211. Epub 2016 Sep 20. No abstract available.

25.

Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.

Pedigo CE, Ducasa GM, Leclercq F, Sloan A, Mitrofanova A, Hashmi T, Molina-David J, Ge M, Lassenius MI, Forsblom C, Lehto M, Groop PH, Kretzler M, Eddy S, Martini S, Reich H, Wahl P, Ghiggeri G, Faul C, Burke GW 3rd, Kretz O, Huber TB, Mendez AJ, Merscher S, Fornoni A.

J Clin Invest. 2016 Sep 1;126(9):3336-50. doi: 10.1172/JCI85939. Epub 2016 Aug 2.

26.

A flexible, multilayered protein scaffold maintains the slit in between glomerular podocytes.

Grahammer F, Wigge C, Schell C, Kretz O, Patrakka J, Schneider S, Klose M, Kind J, Arnold SJ, Habermann A, Bräuniger R, Rinschen MM, Völker L, Bregenzer A, Rubbenstroth D, Boerries M, Kerjaschki D, Miner JH, Walz G, Benzing T, Fornoni A, Frangakis AS, Huber TB.

JCI Insight. 2016 Jun 16;1(9). pii: 86177. doi: 10.1172/jci.insight.86177.

27.

Drug discovery in focal and segmental glomerulosclerosis.

Pullen N, Fornoni A.

Kidney Int. 2016 Jun;89(6):1211-20. doi: 10.1016/j.kint.2015.12.058. Epub 2016 Apr 23. Review.

28.

Systemic and renal lipids in kidney disease development and progression.

Wahl P, Ducasa GM, Fornoni A.

Am J Physiol Renal Physiol. 2016 Mar 15;310(6):F433-45. doi: 10.1152/ajprenal.00375.2015. Epub 2015 Dec 23. Review.

29.

Complete Remission in the Nephrotic Syndrome Study Network.

Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):81-9. doi: 10.2215/CJN.02560315. Epub 2015 Dec 10.

30.

Nonimmunologic targets of immunosuppressive agents in podocytes.

Yoo TH, Fornoni A.

Kidney Res Clin Pract. 2015 Jun;34(2):69-75. doi: 10.1016/j.krcp.2015.03.003. Epub 2015 Apr 9. Review.

31.

Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.

Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstädt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C.

Cell Metab. 2015 Dec 1;22(6):1020-32. doi: 10.1016/j.cmet.2015.09.002. Epub 2015 Oct 1.

32.

Tissue-Engineered Microvasculature to Reperfuse Isolated Renal Glomeruli.

Chang WG, Fornoni A, Tietjen G, Mendez JJ, Niklason LE, Saltzman WM, Pober JS.

Tissue Eng Part A. 2015 Nov;21(21-22):2673-9. doi: 10.1089/ten.TEA.2015.0060. Epub 2015 Oct 1.

33.

CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease.

Bassi R, Fornoni A, Doria A, Fiorina P.

Diabetologia. 2016 Jan;59(1):21-29. doi: 10.1007/s00125-015-3766-6. Epub 2015 Sep 26. Review.

34.

Nephrin Contributes to Insulin Secretion and Affects Mammalian Target of Rapamycin Signaling Independently of Insulin Receptor.

Villarreal R, Mitrofanova A, Maiguel D, Morales X, Jeon J, Grahammer F, Leibiger IB, Guzman J, Fachado A, Yoo TH, Busher Katin A, Gellermann J, Merscher S, Burke GW, Berggren PO, Oh J, Huber TB, Fornoni A.

J Am Soc Nephrol. 2016 Apr;27(4):1029-41. doi: 10.1681/ASN.2015020210. Epub 2015 Sep 23.

35.

Editorial: current perspectives in diabetes and transplantation.

Fornoni A, Vendrame F.

Curr Diabetes Rev. 2015;11(3):134. No abstract available.

36.

Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.

Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl'Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM.

J Am Soc Nephrol. 2015 Sep;26(9):2259-66. doi: 10.1681/ASN.2014080799. Epub 2015 Jan 15.

37.

Insulin signaling: implications for podocyte biology in diabetic kidney disease.

Coward R, Fornoni A.

Curr Opin Nephrol Hypertens. 2015 Jan;24(1):104-10. doi: 10.1097/MNH.0000000000000078.

38.

A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation.

Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, Burke GW, Bruneval P, Naesens M, Jackson A, Alachkar N, Canaud G, Legendre C, Anglicheau D, Reiser J, Sarwal MM.

Sci Transl Med. 2014 Oct 1;6(256):256ra136. doi: 10.1126/scitranslmed.3008538.

39.

Podocyte pathology and nephropathy - sphingolipids in glomerular diseases.

Merscher S, Fornoni A.

Front Endocrinol (Lausanne). 2014 Jul 30;5:127. doi: 10.3389/fendo.2014.00127. eCollection 2014. Review.

40.

Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.

Yoo TH, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, Mitrofanova A, Leclercq F, Faul C, Li J, Kretzler M, Nelson RG, Lehto M, Forsblom C, Groop PH, Reiser J, Burke GW, Fornoni A, Merscher S.

J Am Soc Nephrol. 2015 Jan;26(1):133-47. doi: 10.1681/ASN.2013111213. Epub 2014 Jun 12.

41.

Lipid biology of the podocyte--new perspectives offer new opportunities.

Fornoni A, Merscher S, Kopp JB.

Nat Rev Nephrol. 2014 Jul;10(7):379-88. doi: 10.1038/nrneph.2014.87. Epub 2014 May 27. Review.

42.

Issues in solid-organ transplantation in children: translational research from bench to bedside.

Lipshultz SE, Chandar JJ, Rusconi PG, Fornoni A, Abitbol CL, Burke GW 3rd, Zilleruelo GE, Pham SM, Perez EE, Karnik R, Hunter JA, Dauphin DD, Wilkinson JD.

Clinics (Sao Paulo). 2014;69 Suppl 1:55-72. Review.

43.

Podocyte foot process effacement in postreperfusion allograft biopsies.

Burke GW, Chang JW, Pardo V, Sageshima J, Chen L, Ciancio G, Tsai HL, Wei C, Fornoni A.

Transplantation. 2014 Apr 15;97(7):e38-9. doi: 10.1097/TP.0000000000000053. No abstract available.

44.

The temporal and hierarchical control of transcription factors-induced liver to pancreas transdifferentiation.

Berneman-Zeitouni D, Molakandov K, Elgart M, Mor E, Fornoni A, Domínguez MR, Kerr-Conte J, Ott M, Meivar-Levy I, Ferber S.

PLoS One. 2014 Feb 4;9(2):e87812. doi: 10.1371/journal.pone.0087812. eCollection 2014.

45.

In vivo imaging of kidney glomeruli transplanted into the anterior chamber of the mouse eye.

Kistler AD, Caicedo A, Abdulreda MH, Faul C, Kerjaschki D, Berggren PO, Reiser J, Fornoni A.

Sci Rep. 2014 Jan 27;4:3872. doi: 10.1038/srep03872.

46.

Rituximab: a boot to protect the foot.

Reiser J, Fornoni A.

J Am Soc Nephrol. 2014 Apr;25(4):647-8. doi: 10.1681/ASN.2013121331. Epub 2014 Jan 23. No abstract available.

47.

Diabetic nephropathy: Is it time yet for routine kidney biopsy?

Gonzalez Suarez ML, Thomas DB, Barisoni L, Fornoni A.

World J Diabetes. 2013 Dec 15;4(6):245-55. doi: 10.4239/wjd.v4.i6.245. Review.

48.

Abatacept in B7-1-positive proteinuric kidney disease.

Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW 3rd, Mundel P.

N Engl J Med. 2013 Dec 19;369(25):2416-23. doi: 10.1056/NEJMoa1304572. Epub 2013 Nov 8.

49.

Podocyte-specific GLUT4-deficient mice have fewer and larger podocytes and are protected from diabetic nephropathy.

Guzman J, Jauregui AN, Merscher-Gomez S, Maiguel D, Muresan C, Mitrofanova A, Diez-Sampedro A, Szust J, Yoo TH, Villarreal R, Pedigo C, Molano RD, Johnson K, Kahn B, Hartleben B, Huber TB, Saha J, Burke GW 3rd, Abel ED, Brosius FC, Fornoni A.

Diabetes. 2014 Feb;63(2):701-14. doi: 10.2337/db13-0752. Epub 2013 Oct 7.

50.

Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.

Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, Burke G, Rabb H, Kakkad K, Reiser J, Estrella MM.

Transplantation. 2013 Oct 15;96(7):649-56. doi: 10.1097/TP.0b013e31829eda4f.

Supplemental Content

Loading ...
Support Center